This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D61.9 | Synonyms: Panmyelopenia, panmyelohypoplasia, panmyeloaplasia
"Panmyelophthisis" is a term derived from the Greek pan (all), myelo (marrow), and phthisis (wasting, devastation), meaning a state in which all hematopoietic cell lineages of the bone marrow are globally lost. The term began to be used in European hematology literature in the early 20th century and developed into a pathological descriptive term for the severe form or comprehensive lesion of aplastic anemia.
With advances in bone marrow pathology research in the 1920s–1940s, the pattern of global cell loss observed on bone marrow biopsy began to be systematically described. Frugoni (1930s) and Di Guglielmo (1940s) of the Italian school contributed to systematizing the pathological characteristics of panmyelophthisis. Later, Dameshek and Gunz, in their 1958 book "Leukemia", clearly described the relationship between global marrow loss and hematopoietic failure.
Modern treatment of severe aplastic anemia, including panmyelophthisis, reached a turning point with the successful bone marrow transplantation by Thomas et al. in 1972. The study by Speck et al. published in 1976 first reported that antilymphocyte globulin (ALG) is effective for hematopoietic recovery in patients with aplastic anemia, suggesting that immune mechanisms are involved in the pathogenesis.
In modern hematology, panmyelophthisis is used as a histopathological term describing a state of severe loss of bone marrow function rather than as an independent disease entity, and in the ICD-10 classification it is included in D61.9 (aplastic anemia, unspecified).
The most important cause of panmyelophthisis is a T lymphocyte–mediated autoimmune response. Autoreactive CD8+ T cells and CD4+ Th1 cells target and attack hematopoietic stem cells and hematopoietic progenitor cells, globally suppressing the production of all blood cell lineages.
High-dose irradiation, anticancer chemotherapy (especially alkylating agents), benzene and its derivatives, chloramphenicol, and others can cause global damage to the bone marrow. These substances directly destroy hematopoietic stem cells with self-renewal capacity through cytotoxic mechanisms.
Severe infections with EBV, CMV, and parvovirus B19 can cause widespread destruction of bone marrow cells. Hepatitis-associated aplastic anaemia is a special form of panmyelophthisis that runs a severe course, mainly in young men.
Fanconi anaemia, if untreated, eventually progresses to a state of panmyelophthisis. Dyskeratosis congenita, Shwachman-Diamond syndrome, and others can also eventually cause global marrow loss.
In acquired panmyelophthisis/aplastic anemia, prevalence is higher in carriers of the HLA-DRB1*15:01 and HLA-DRB1*15:02 alleles. This suggests that specific HLA molecules promote activation of autoreactive T cells through presentation of autoantigens.
In about 30% of patients with panmyelophthisis, telomere length is short, below the 10th percentile for age. TERT and TERC variants can also be found in acquired aplastic anemia, suggesting that the boundary between hereditary and acquired forms is continuous.
Panmyelophthisis is the most severe form of aplastic anemia and overlaps considerably with severe and very severe aplastic anemia. The annual incidence of severe aplastic anemia is 1–2 per million in the West and higher in East Asia at 2–4 per million.
As in aplastic anemia overall, the age distribution at onset is bimodal, at 15–25 years and 60 years or older. Post-hepatitis panmyelophthisis shows a markedly higher incidence in young men (10–30 years).
The frequency of patients with severe aplastic anemia (including panmyelophthisis) in Korea is similar to that in Japan and other East Asian countries, at 2–3 times the Western level. According to Health Insurance Review & Assessment Service (HIRA) statistics, the number of patients with aplastic anemia in Korea is estimated at about 10,000–15,000 per year.
In panmyelophthisis, multipotent hematopoietic stem cells and hematopoietic progenitor cells of all lineages are destroyed together. T cell–mediated immune attack targets not merely progenitor cells of a particular lineage but the multipotent hematopoietic stem cells (HSCs) themselves, so production across the erythroid, leukocyte, and platelet lineages declines simultaneously.
IFN-γ secreted by activated T cells upregulates FAS expression on hematopoietic stem cells and induces apoptosis via the Fas-FasL pathway. TNF-α impairs the hematopoiesis-supporting function of bone marrow stromal cells and inhibits progenitor cell proliferation. This cytokine storm explains the rapid progression of panmyelophthisis.
Damage to the supporting marrow stroma, inhibition of angiogenesis, and changes in extracellular matrix components combine to destroy the hematopoietic microenvironment. As adipocytes replace the hematopoietic space, the marrow is converted to fatty marrow, and residual hematopoietic cells form extremely rare scattered colonies.
The symptoms of panmyelophthisis reflect the triad of pancytopenia: ① symptoms of anemia (fatigue, pallor, dyspnea, palpitations), ② symptoms of thrombocytopenia (petechiae, purpura, bleeding tendency), ③ symptoms of neutropenia (recurrent infections, fever).
Panmyelophthisis shows more severe pancytopenia than ordinary aplastic anemia, and symptoms develop more abruptly and seriously. When the absolute neutrophil count is less than 200/μL (very severe), life-threatening sepsis can progress rapidly. With platelets below 10,000/μL, the risk of spontaneous internal bleeding (cerebral hemorrhage, gastrointestinal bleeding) is high.
General weakness, weight loss, and fever (often due to infection) may occur. Heart failure, pulmonary edema, and end-organ dysfunction due to severe anemia may accompany it.
Pallor (conjunctival pallor, mucosal pallor), petechiae, purpura, and bruising are characteristic physical findings. High fever (with infection), tachycardia, and hypotension may be observed. Lymphadenopathy and splenomegaly are generally absent, and if present, other causes (lymphoma, MDS, etc.) are strongly suspected.
Severe tricytopenia is seen, with hemoglobin <6–7 g/dL, platelets <10,000–20,000/μL, and ANC <200–500/μL. The absolute reticulocyte count is markedly reduced (<10,000/μL). Dysplasia on the peripheral blood smear is minimal, and findings are mainly of normocytic anemia.
Bone marrow biopsy shows markedly reduced cellularity (generally <10%), with the marrow space mostly filled with adipocytes. Residual hematopoietic cells form extremely rare scattered small colonies, and dysplasia is absent or minimal. This "empty marrow" finding corresponds to the histopathological definition of panmyelophthisis.
Immediate bone marrow examination is required when unexplained severe pancytopenia is found. CBC and reticulocyte count are the primary screening tests. If there are no dysplastic cells on the blood smear and pancytopenia is present, a bone marrow failure state including panmyelophthisis is suspected.
If ANC <500/μL or platelets <20,000/μL, immediate bone marrow evaluation and infection management are required. Panmyelophthisis is treated as a hematologic emergency, and evaluation at a specialized hematology center is recommended.
In children and adults under 40 years of age, DEB or MMC chromosomal fragility testing (to exclude Fanconi anemia) and telomere length measurement (to exclude dyskeratosis congenita) are mandatory to differentiate inherited bone marrow failure syndromes.
The key diagnostic finding on bone marrow biopsy is cellularity <25% with global loss of all hematopoietic lineages (erythroid, myeloid, megakaryocytic). An "empty marrow" or "fatty marrow" finding is specific to panmyelophthisis.
According to the Camitta criteria, cases are classified as severe SAA (at least 2 of ANC <500/μL + platelets <20,000/μL + reticulocytes <20,000/μL, plus bone marrow cellularity <25%) and very severe vSAA (ANC <200/μL). Panmyelophthisis generally corresponds to SAA or vSAA.
| Differential diagnosis | Key differentiating findings | Test |
|---|---|---|
| Hypocellular MDS | Presence of dysplastic cells, chromosomal abnormalities | Cytogenetics, NGS somatic variants |
| Hypocellular AML | Increased blasts in bone marrow (>20%) | Bone marrow biopsy, immunohistochemistry |
| PNH | CD55/CD59-deficient clone | Flow cytometry |
| LGL leukemia | Increased large granular lymphocytes | Blood smear, T-cell immunophenotyping |
| Bone marrow infiltration (lymphoma, metastatic cancer) | Identification of infiltrating cells | Bone marrow biopsy, immunohistochemistry |
Panmyelophthisis is a hematologic emergency requiring immediate transfusion support (red blood cells, platelets), broad-spectrum antibacterial and antifungal therapy (febrile neutropenia protocol), and infection prevention measures such as isolation.
In severe or very severe aplastic anemia (panmyelophthisis) in patients aged 40 or younger, HSCT from an HLA-matched sibling or unrelated donor is the best treatment. Performing transplantation as soon as possible after diagnosis (ideally within 3–6 months) favors outcomes. Recently, improved outcomes of haploidentical HSCT have broadened the donor pool.
When HSCT is not indicated, triple immunosuppressive therapy with antithymocyte globulin (ATG) + cyclosporine A + eltrombopag is given. Horse-derived ATG (hATG) generally shows a better response rate than rabbit ATG (rATG) in first-line IST.
The prognosis of untreated panmyelophthisis/very severe aplastic anemia is extremely poor, with mortality within 1 year of diagnosis reaching 80–90%. The main causes of death are infection (sepsis, fungal pneumonia) and bleeding (cerebral hemorrhage, gastrointestinal bleeding).
The 5-year survival rate has improved to 85–95% with HLA-matched sibling donor HSCT and 70–80% with HLA-matched unrelated donor HSCT. Recently improved outcomes of haploidentical HSCT have expanded opportunities even for patients without a donor.
Clonal evolution (MDS, AML), emergence of PNH, GVHD after HSCT, iron overload (in transfusion-dependent patients), and secondary malignancies are major issues in long-term survivors. With triple therapy of ATG + cyclosporine + eltrombopag, overall response rates of 68–94% are reported, but because of the risk of relapse (30–40%) and clonal evolution (5–15%), long-term follow-up is essential.
Minimize occupational and environmental exposure to myelotoxic substances such as benzene, aromatic hydrocarbons, and organic solvents. Strengthen monitoring for myelotoxicity in patients who have received chemotherapy and radiation therapy.
If there is a family history of inherited bone marrow failure such as Fanconi anemia, genetic counseling and screening of family members are performed. Affected births can be prevented through prenatal diagnosis or preimplantation genetic testing.
In patients receiving immunosuppressive therapy, appropriate infection prevention protocols (PCP prophylaxis, antifungal prophylaxis, vaccination) are implemented. Vaccination against varicella, influenza, and pneumococcus is recommended.